Why are we still using cisplatin?
Cancer Chemotherapy and Pharmacology · 09.04.2026 · 96 (1)
DOI: 10.1007/s00280-026-04882-0 ↗Kurz gefasst
Leserbrief in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 09.04.2026. Verfasst von Jemma Arakelyan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong Science Park, Hong Kong, China. jemmaarakelyan93@gmail.com. Hauptthemen laut MEDLINE: Antineoplastic Agents, Cisplatin, Neoplasms. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong Science Park, Hong Kong, China. jemmaarakelyan93@gmail.com.
- Department of Clinical Oncology, The Chinese University of Hong Kong, Hong Kong, China.
- Centre for Haematology, Department of Immunology and Inflammation, Imperial College London, London, UK.
- Department of Haematology, Peking University People's Hospital, Beijing, China.
- Laboratory for Synthetic Chemistry and Chemical Biology Limited, Hong Kong Science Park, Hong Kong, China.
Zitieren
APA
Arakelyan, J., Loong, H., Gale, R. P., & Che, C. M. (2026). Why are we still using cisplatin?. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04882-0
Vancouver
Arakelyan J, Loong H, Gale RP, Che CM. Why are we still using cisplatin?. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04882-0
BibTeX
@article{Arakelyan2026,
author = {Arakelyan, Jemma and Loong, Herbert and Gale, Robert Peter and Che, Chi-Ming},
title = {Why are we still using cisplatin?},
journal = {Cancer Chemotherapy and Pharmacology},
year = {2026},
volume = {96},
number = {1},
doi = {10.1007/s00280-026-04882-0}
}
EUVIMED